Arrowhead to Present SHASTA-3/4 12-Month Data at ESC 2026
Aug 24, 2026, 7:37 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
ESC-based catalysts for phase 3 readouts historically prompt risk-on moves for biotech names with late-stage data, especially when the drug target (ANGPTL3) has broader lipid-lowering relevance. Positive 12-month TG reductions could support ARWR's valuation of the TRiM platform and REDEMPLO's commercial potential; negative results would raise risk of a pullback. Given the high expectations, a move could occur in the 1–4 week window around ESC timing.
AI summary
What happened, with direct paths to the underlying reporting
Arrowhead will unveil 12-month SHASTA-3/4 data for plozasiran in severe hypertriglyceridemia at ESC 2026 and host a webcast to discuss the results. Positive outcomes could bolster confidence in ARWR's TRiM platform and potentially drive licensing or collaboration momentum for REDEMPLO and HoFH programs.
ESC 2026 presents 12-month SHASTA-3/SHASTA-4 data for plozasiran. Potential ARWR valuation catalyst.
Arrowhead investor webcast Aug 31 to review ESC data. Key near-term catalyst.
REDEMPLO status and Sanofi Greater China rights.
SHASTA-3/SHASTA-4 involve ~750 participants; 25 mg every 3 months.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Arrowhead reported Phase 3 plozasiran results showing robust triglyceride reductions and fewer pancreatitis events, prompting an FDA supplemental NDA submission planned for by end…
FDA approved Arrowhead's drug for a genetic disorder causing extremely high blood triglycerides. Approval establishes commercial pathway and materially de-risks Arrowhead's lead p…
